TWI387460B - Extraction methods and compositions to ameliorate hyperlipidemia, hyperglycermia and fatty liver - Google Patents
Extraction methods and compositions to ameliorate hyperlipidemia, hyperglycermia and fatty liver Download PDFInfo
- Publication number
- TWI387460B TWI387460B TW98121165A TW98121165A TWI387460B TW I387460 B TWI387460 B TW I387460B TW 98121165 A TW98121165 A TW 98121165A TW 98121165 A TW98121165 A TW 98121165A TW I387460 B TWI387460 B TW I387460B
- Authority
- TW
- Taiwan
- Prior art keywords
- powder
- hours
- fatty liver
- residue
- bitter gourd
- Prior art date
Links
- 208000004930 Fatty Liver Diseases 0.000 title claims description 17
- 206010019708 Hepatic steatosis Diseases 0.000 title claims description 17
- 208000010706 fatty liver disease Diseases 0.000 title claims description 17
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims description 17
- 239000000203 mixture Substances 0.000 title claims description 11
- 238000000605 extraction Methods 0.000 title claims description 7
- 208000031226 Hyperlipidaemia Diseases 0.000 title description 3
- 239000008280 blood Substances 0.000 claims description 30
- 210000004369 blood Anatomy 0.000 claims description 30
- 239000000843 powder Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 102000023984 PPAR alpha Human genes 0.000 claims description 14
- 108010016731 PPAR gamma Proteins 0.000 claims description 14
- 102000000536 PPAR gamma Human genes 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- 241000195628 Chlorophyta Species 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 241000202807 Glycyrrhiza Species 0.000 claims description 10
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 10
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 10
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 10
- 235000009811 Momordica charantia Nutrition 0.000 claims description 10
- 229940010454 licorice Drugs 0.000 claims description 10
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 claims description 9
- 235000020383 bitter gourd juice Nutrition 0.000 claims description 9
- 150000002632 lipids Chemical class 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 108010028924 PPAR alpha Proteins 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 239000002808 molecular sieve Substances 0.000 claims description 8
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 8
- 108010073771 Soybean Proteins Proteins 0.000 claims description 5
- 229940069445 licorice extract Drugs 0.000 claims description 5
- 229940001941 soy protein Drugs 0.000 claims description 5
- 102000005593 Endopeptidases Human genes 0.000 claims description 4
- 108010059378 Endopeptidases Proteins 0.000 claims description 4
- 235000019764 Soybean Meal Nutrition 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 239000004455 soybean meal Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 244000078912 Trichosanthes cucumerina Species 0.000 claims 4
- 208000013016 Hypoglycemia Diseases 0.000 claims 2
- 230000000055 hyoplipidemic effect Effects 0.000 claims 2
- 230000002218 hypoglycaemic effect Effects 0.000 claims 2
- 238000000354 decomposition reaction Methods 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000002791 soaking Methods 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000000463 material Substances 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 230000004913 activation Effects 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 102000003929 Transaminases Human genes 0.000 description 7
- 108090000340 Transaminases Proteins 0.000 description 7
- 244000302512 Momordica charantia Species 0.000 description 6
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 6
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 229940123464 Thiazolidinedione Drugs 0.000 description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- -1 brome amino acid Chemical class 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 150000001467 thiazolidinediones Chemical class 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Description
一種保健食品之配方組合及其各素材之抽出方法Formulation combination of health food and extraction method of each material thereof
在已開發國家中,脂質與醣類代謝不佳,容易產生代謝症候群的症狀,如糖尿病、高血壓、高血脂、動脈硬化、高三酸甘油酯等疾病,然近年來的研究發現,這些疾病都與細胞核中的受體-PPARs(脂小體活化增生受體)有關。目前有許多科學家都在找尋可以活化PPARs的活化子當成代謝症候群的藥物,例如:thiazolidinediones(TZD)(胰島素增敏劑)為活化PPARγ而具有降血糖的效果,而fibrates(苯氧芳雙類)為活化PPARα且有降血脂的效果,但由於以上皆屬於藥物,同時具有副作用,不適合長期食用。In developed countries, lipids and carbohydrates are poorly metabolized, and they are prone to symptoms of metabolic syndrome, such as diabetes, hypertension, hyperlipidemia, arteriosclerosis, and high triglycerides. However, recent studies have found that these diseases are It is associated with receptor-PPARs (liposome-activated proliferating receptors) in the nucleus. Many scientists are currently looking for drugs that activate PPARs as metabolic syndromes. For example, thiazolidinediones (TZD) (insulin sensitizer) has the effect of lowering blood glucose by activating PPARγ, while fibrates (phenoxy aryl) In order to activate PPARα and have the effect of lowering blood fat, but because all of the above are drugs, and have side effects, it is not suitable for long-term consumption.
近年來,有少量文獻由一些古方常用的降血糖素材,驗證是否是經由活化PPARγ而達到降血糖的效果,並期望可以由這些天然的成分去找尋更強可以活化PPAR的化合物,以便進行藥物的開發。目前文獻的素材都是以單方為主,例如:啤酒花抽出物可以同時活化PPARα及γ、苦瓜抽出物可以同時活化PPARα及γ、甘草抽出物活化PPARγ...等,但這些有效成分往往需要經過特殊的有機溶劑去萃取,才可以獲得有效的成分。但以食品的觀念,經過有機溶劑萃取並不適合應用於食品。所以本專利就是利用特殊酒精和/或水的抽取及配合最佳之各素材之組合比例,以獲得最有效(血脂、血糖、脂肪肝)的食品複方配方。In recent years, a small amount of literature has been used to reduce blood glucose by activating PPARγ, and it is expected that these natural ingredients can be used to find stronger compounds that can activate PPAR for drug use. Development. At present, the materials in the literature are mainly unilateral. For example, hop extracts can simultaneously activate PPARα and γ, bitter melon extract can simultaneously activate PPARα and γ, licorice extract activates PPARγ, etc., but these active ingredients often need to pass through. Special organic solvents are extracted to obtain effective ingredients. However, in the concept of food, organic solvent extraction is not suitable for food. Therefore, this patent is to use the combination of special alcohol and / or water and the best combination of materials to obtain the most effective food formula for blood lipids, blood sugar, fatty liver.
目前降血糖及降血脂的藥物有許多都是經由活化PPAR α及γ所開發完成,所以功效及機制原理已經經過許多專家學者確認,但是這一類的藥品,往往因為化學合成的化合物,而使一些受試者產生肝臟或腎臟的毒性,因而使身體的GOT(麩氨基酸草醋酸轉氨基酵素)及GPT(麩氨基酸焦葡萄轉氨基酵素)值變高,所以本專利的想法就是利用醫藥界找尋活化活化物的方法,對於目前人類常吃的素材以食品可用的溶劑進行篩選,找出具有活化PPAR α及γ天然化合物或複方組合,以造福更多的人。Many of the drugs for lowering blood sugar and lowering blood fat have been developed through the activation of PPAR α and γ. Therefore, the principle of efficacy and mechanism has been confirmed by many experts and scholars, but this type of medicine is often caused by chemically synthesized compounds. The subject produces liver or kidney toxicity, which makes the body's GOT (breast amino acid acetic acid transaminase) and GPT (brome amino acid pyroglucan amino acid) values higher, so the idea of this patent is to use the medical community to find activation. The method of activating substances is to screen the materials which are commonly eaten by humans in foods, and to find out those having activated PPAR α and γ natural compounds or compound combinations for the benefit of more people.
本創意是一種具有調降血糖血脂以及改善脂肪肝的多效複方食品組合及其抽取方法,其特徵在於添加比例為苦瓜20~40%、甘草1%~10%、綠藻15%~30%、大豆蛋白粉20~40%。而其各素材抽出物之抽取方法分別如下:The present invention is a multi-effect compound food combination and a method for extracting the same, which are characterized in that the ratio of addition is 20~40% of bitter gourd, 1%~10% of licorice, 15%~30% of green algae. Soy protein powder 20~40%. The extraction methods of each material extraction are as follows:
甲、苦瓜抽出物:100克新鮮苦瓜先以榨汁機榨取苦瓜汁液,剩餘的殘渣再以100~200 ml 90%以上的酒精浸泡6至8個小時後,過濾去除殘渣,把苦瓜汁液和酒精抽提物混合進行冷凍乾燥,製成粉末而成。A, bitter gourd extract: 100 grams of fresh bitter gourd juice extracts bitter gourd juice, the remaining residue is then soaked in 100 ~ 200 ml 90% alcohol for 6 to 8 hours, filtered to remove residue, bitter gourd juice and alcohol The extract is mixed and freeze-dried to form a powder.
乙、甘草抽出物:100克甘草經過粉碎後,加入500~1000ml體積的純水以60~100rpm振盪室溫浸泡10小時以上,除去甘草殘渣後,將上清液冷凍乾燥成粉末,此一粉末再以50~100ml甲醇浸泡20小時以上,將醇溶的部份再乾燥成粉末而成。B, licorice extract: 100 grams of licorice after pulverization, add 500 ~ 1000ml volume of pure water at 60 ~ 100rpm shaking room temperature for more than 10 hours, remove the licorice residue, the supernatant is freeze-dried into a powder, this powder The mixture is further immersed in 50-100 ml of methanol for more than 20 hours, and the alcohol-soluble portion is further dried into a powder.
丙、破壁綠藻:100克破壁綠藻粉,以500~1000 ml 100℃沸水進行抽取60~180分鐘,將此水溶液以10mm-5 mm以分子篩過濾,除去殘渣部份,水溶液部分進行濃縮與乾燥噴粉而成。C, broken wall green algae: 100 grams of broken green algae powder, 500 ~ 1000 ml 100 ° C boiling water for 60 ~ 180 minutes, the aqueous solution is filtered with 10ml - 5 mm molecular sieve, remove the residue part, the aqueous solution part Concentrated and dried powdered.
丁、大豆蛋白粉:100克脫油的豆粕,以300~500ml的水,加入0.3%~3%蛋白分解酵素endopeptidase(E.C.3.4.24.28),於45-50度下作用6-8小時,經過過濾,取濾液,以分子篩過濾取10000 Dalton以下的成分。Ding, soy protein powder: 100 grams of deoiled soybean meal, with 300~500ml of water, adding 0.3%~3% proteolytic enzyme endopeptidase (EC3.4.24.28), acting at 45-50 degrees for 6-8 hours, after Filtration, taking the filtrate, and filtering with a molecular sieve to obtain a component of 10,000 Dalton or less.
將上述的配方組成進行動物與人體試驗的使用,證實有調降血脂、血糖與改善脂肪肝的功效,且以上製程的複方組合效果好具有好的水中擴散性,可以應用其他複方食品組合,包括膠囊錠劑、穀粉、飲料、口服液產品的開發。The above formula is used for animal and human test, which proves that it has the effects of lowering blood fat, blood sugar and improving fatty liver, and the combination of the above processes has good water diffusion property, and other compound food combinations can be applied, including Development of capsule lozenges, cereal flour, beverages, and oral liquid products.
利用所建立轉染PPAR α及PPAR γ之細胞的方法(transactivation assay system)(轉染細胞活化系統)---於活化PPAR啟動子基因的後方,接入冷光的基因,再把此基因送入表現的肝臟細胞,接著使用素材去刺激細胞,當素材具有活化PPAR的能力,即可以由冷光儀測出冷光的強弱變化,以此決定素材活化PPAR α及PPAR γ的效果,也可以應用此技術決定製程及搭配複方組合。Using the transactivation assay system (transfected cell activation system) that has been established to transfect PPAR alpha and PPAR gamma - to activate the PPAR promoter gene, access the luminescent gene, and then send the gene into The liver cells are expressed, and then the material is used to stimulate the cells. When the material has the ability to activate PPAR, the intensity of cold light can be measured by a luminometer to determine the effect of the material on the activation of PPAR α and PPAR γ. Decide on the process and match the combination.
經過對許多食品素材進行篩選,發現以下四個素材有很好的活性,並進行不同萃取方式,找出以下的專利製程,有最好的活化PPAR效果,製造的方法如下:After screening a lot of food materials, the following four materials were found to be very active, and different extraction methods were carried out to find out the following patented processes, which have the best activated PPAR effect. The manufacturing methods are as follows:
甲、苦瓜抽出物:100克新鮮苦瓜先以榨汁機榨取苦瓜汁液,餘殘的渣再以100~200 ml 90%以上的酒精浸泡6至8個小時後,過濾去除殘渣,把苦瓜汁液和酒精抽提物混合進行冷凍乾燥,製成粉末而成。A, bitter gourd extract: 100 grams of fresh bitter gourd first extract the bitter gourd juice with a juicer, and the remaining residue is soaked in 100~200 ml 90% alcohol for 6-8 hours, filtered to remove the residue, and the bitter gourd juice and The alcohol extract is mixed and freeze-dried to form a powder.
乙、甘草抽出物:100克甘草經過粉碎後,加入500~1000ml體積的純水以60~100rpm振盪室溫浸泡10小時以上,除去甘草殘渣後將上清液冷凍乾燥成粉末,此一粉末再以50~100ml甲醇浸泡20小時以上,將醇溶的部份再乾燥成粉末而成。B, licorice extract: 100 grams of licorice after pulverization, add 500 ~ 1000ml volume of pure water at 60 ~ 100rpm shaking room temperature for more than 10 hours, remove the licorice residue, the supernatant is freeze-dried into a powder, this powder and then Soak in 50-100 ml of methanol for more than 20 hours, and then dry the alcohol-soluble portion into a powder.
丙、破壁綠藻:100克破壁綠藻粉,以500~1000 ml 100℃沸水進行抽取60~180分鐘,將此水溶液以10mm-5 mm以分子篩過濾,除去殘渣部份,水溶液部分進行濃縮與乾燥噴粉而成。C, broken wall green algae: 100 grams of broken green algae powder, 500 ~ 1000 ml 100 ° C boiling water for 60 ~ 180 minutes, the aqueous solution is filtered with 10ml - 5 mm molecular sieve, remove the residue part, the aqueous solution part Concentrated and dried powdered.
丁、大豆蛋白粉:100克脫油的豆粕,以300~500ml的水,加入0.3%~3%蛋白分解酵素endopeptidase(E.C.3.4.24.28),於45-50度下作用6-8小時,經過過濾,取濾液,以分子篩過濾取10000 Dalton以下的成分。Ding, soy protein powder: 100 grams of deoiled soybean meal, with 300~500ml of water, adding 0.3%~3% proteolytic enzyme endopeptidase (EC3.4.24.28), acting at 45-50 degrees for 6-8 hours, after Filtration, taking the filtrate, and filtering with a molecular sieve to obtain a component of 10,000 Dalton or less.
接著進行複方的組合及搭配,利用以上四個專利製程所抽取的素材,找出最佳的誘發劑量的活性,此外也進行素材排列組合,實驗結果發現這四種素材搭配在一起後,經過PPAR α及PPAR γ之細胞株篩選方法確定效果比單方或是其他配方任意組合(總濃度相同下比較)有更好的活化PPAR α及PPAR γ的能力(如下圖一及圖二)。圖一:表示活化PPAR α的倍數,圖二表示活化PPAR γ的倍數。而控制組為只用水去刺激細胞的結果,定其活化倍數為100%(1倍),而甘草、苦瓜、綠藻、大豆其對PPARα的最高活化程度只有1.5、1.4、2.3、2.1倍,當四個成份組合一起時,PPARα的最高活化程度可以高達5.3倍,而四個單方對PPARγ的最高活化程度分別為2.9、1.3、1.8、1.9倍,當四個成份組合一起時,對PPARγ的最高活化程度高達5.0倍,以上結果証實此複方組合具有可加成活化PPARα和γ的效果,優於單方的組合,有其進步性。Then carry out the combination and matching of the compound, and use the materials extracted by the above four patent processes to find the best dose-inducing activity. In addition, the material arrangement and combination are also carried out. The experimental results show that the four materials are matched together and pass the PPAR. The screening method for α and PPAR γ cell lines has better ability to activate PPAR α and PPAR γ than any combination of unilateral or other formulations (compared to the same total concentration) (see Figure 1 and Figure 2 below). Figure 1: shows the multiple of activated PPAR α, and Figure 2 shows the multiple of activated PPAR γ. The control group was the result of only stimulating the cells with water, and the activation factor was 100% (1 time), while the highest activation degree of PPARα was only 1.5, 1.4, 2.3, 2.1 times for licorice, bitter gourd, green algae and soybean. When the four components are combined, the highest activation degree of PPARα can be as high as 5.3 times, and the maximum activation degree of four unilateral PPARγ is 2.9, 1.3, 1.8, 1.9 times, respectively. When the four components are combined, the PPARγ is combined. The highest activation degree is up to 5.0 times. The above results confirm that the compound combination has the effect of adding PPARα and γ, which is superior to the single combination and has progress.
將上述的配方組合進一步進行血脂、血糖與脂肪肝的體內試驗,以進一步證實其功效The above formula combination is further tested in vivo for blood lipids, blood sugar and fatty liver to further confirm its efficacy
■血脂血糖動物實驗: 以成大動物中心所購買的C57BL/6品系老鼠,經過高脂肪飼料的誘發,使老鼠產生高血糖及高血脂的症狀,經過我們設計的配方餵食老鼠,可以發現老鼠經過3個星期餵食後,具有降血糖(14.6%)及三酸甘油酯(21.8%)的效果,而在第六個星期可以看到降膽固醇(12.4%)的效果。 ■ Blood Lipid Blood Sugar Animal Experiment: C57BL/6 strain mice purchased from Chengda Animal Center, induced by high-fat diet, cause hyperglycemia and hyperlipidemia in mice. After we designed the mice, we can find the mice. After 3 weeks of feeding, it had the effect of lowering blood sugar (14.6%) and triglyceride (21.8%), and in the sixth week, the effect of lowering cholesterol (12.4%) was observed.
■血脂血糖人體體驗: 在血糖體驗者部份,經過一個月的服用,血糖平均值由99.1 mg/dl降至94.3mg/dl(降幅5%)。而在血脂體驗者的部分,經過一個月的測試,所有體驗者的膽固醇平均值由233 mg/dl降至207 mg/dl(降幅11.1%);而三酸甘油酯的平均值由221mg/dl降至162mg/dl(降幅26.7%),體驗者有高達100%的滿意效果。體驗期間體驗者的肝臟指數(麩氨基酸草醋酸轉氨基酵素及麩氨基酸焦葡萄轉氨基酵素)及腎臟指數(肌酸酐),都沒有上升,甚至還下降,證實專利配方安全不會造成肝、腎的負擔。當體驗者不繼續服用專利配方(超過一個月),就可以看到體驗者的血糖及血脂(除了三酸甘油酯)都有回升現象,證實所降的血糖、血脂為專利配方的效果。 ■ Blood lipids Blood sugar human experience: In the blood sugar experience part, after one month of taking, the average blood glucose level decreased from 99.1 mg/dl to 94.3 mg/dl (a decrease of 5%). In the blood lipid experience part, after one month of testing, the average cholesterol value of all experiencers decreased from 233 mg/dl to 207 mg/dl (a decrease of 11.1%); while the average value of triglycerides was 221 mg/dl. Dropped to 162mg/dl (down 26.7%), the experience has a 100% satisfaction. During the experience period, the experiencer's liver index (breast amino acid acetic acid transaminase and bran amino acid pyrogal aminotransferase) and kidney index (creatinine) did not rise or even decreased, confirming that the patented formula would not cause liver and kidney. The burden. When the experiencer does not continue to take the patented formula (more than one month), it can be seen that the blood sugar and blood lipids (except triglycerides) of the experiencer have rebounded, confirming that the lowered blood sugar and blood lipids are the effects of the patented formula.
■脂肪肝動物實驗: 以成大動物中心所購買的C57BL/6品系老鼠,經過高脂肪及高果糖飼料誘發,並於飲水中加入酒精,使老鼠產生脂肪肝的症狀,經過我們設計的配方餵食老鼠,可以發現老鼠經過2個月餵食後,可以調降肝指數(麩氨基酸焦葡萄轉氨基酵素),有服用專利配方老鼠的麩氨基酸焦葡萄轉氨基酵素指數由50U/L降到36U/L,沒有服用專利配方控制組的麩氨基酸焦葡萄轉氨基酵素指數由51U/L上升到55U/L。另外也犧牲老鼠,由老鼠的肝臟可以發現,有服用配方老鼠的肝臟三酸甘油酯含量平均為23mg,沒有服用配方的控制組平均為28mg,且有顯著差異,而老鼠腹部以及皮下的脂肪,服用專利配方明顯比沒有服用的低,因此此專利配方具有減少脂肪堆積之效。■ Fatty liver animal experiment: C57BL/6 strain mice purchased by Chengda Animal Center were induced by high fat and high fructose feed, and alcohol was added to the drinking water to make the rats develop symptoms of fatty liver. In mice, it can be found that after 2 months of feeding, the rats can reduce the liver index (brome amino acid pyramid aminotransferase), and the transglutaminase amino acid enzyme index of the patented formula mouse is reduced from 50 U/L to 36 U/L. The transaminase index of the bran amino acid coke grape without the patented formula control group increased from 51 U/L to 55 U/L. In addition, the rats were sacrificed. The liver of the mice was found to have an average of 23 mg of liver triglyceride in the formula-treated mice and 28 mg in the control group without the formula, and there was a significant difference in the abdominal and subcutaneous fat of the mice. The patented formula is significantly lower than that not taken, so this patented formula has the effect of reducing fat accumulation.
■脂肪肝人體實驗: 此專利配方進行人體體驗,三個月後,可以看到平均生化值有調降的效果,包括麩氨基酸草醋酸轉氨基酵素(由46U/L調降到30U/L),麩氨基酸焦葡萄轉氨基酵素(由45U/L調降到35U/L),三酸甘油酯(由204mg/dl調降到169mg/dl),總膽固醇(由220mg/dl調降到200mg/dl)都有明顯的改善,甚至有多位體驗者可以在3個月內,由超音波判斷的中度脂肪肝改善成為輕度或輕中度脂肪肝。■ Fatty liver human experiment: This patented formula for human experience, after three months, you can see the effect of the reduction of the average biochemical value, including bran amino acid grass acetic acid transaminase (from 46U / L down to 30U / L) , Bran amino acid Jiao grape transaminase (from 45U / L down to 35U / L), triglyceride (from 204mg / dl down to 169mg / dl), total cholesterol (from 220mg / dl down to 200mg / Dl) has obvious improvement, even a number of experiencers can improve the moderate fatty liver judged by ultrasound to mild or mild to moderate fatty liver within 3 months.
目前此專利配方不同於市面上只作用於腸胃道,抑制油脂吸收的產品,且市面上也沒有同時訴求降血糖及降血脂以及改善脂肪肝多效的產品,所以這個專利配方及其各素材之抽出法,是具有新穎性及進步性、產業利用之專利要件。At present, this patented formula is different from the products that only act on the gastrointestinal tract and inhibit the absorption of oil, and there is no product in the market that simultaneously appeals to lowering blood sugar and lowering blood fat and improving fatty liver. Therefore, this patent formula and its materials are The extraction method is a patent element with novelty and progressiveness and industrial utilization.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW98121165A TWI387460B (en) | 2009-06-24 | 2009-06-24 | Extraction methods and compositions to ameliorate hyperlipidemia, hyperglycermia and fatty liver |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW98121165A TWI387460B (en) | 2009-06-24 | 2009-06-24 | Extraction methods and compositions to ameliorate hyperlipidemia, hyperglycermia and fatty liver |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201100088A TW201100088A (en) | 2011-01-01 |
TWI387460B true TWI387460B (en) | 2013-03-01 |
Family
ID=44836453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW98121165A TWI387460B (en) | 2009-06-24 | 2009-06-24 | Extraction methods and compositions to ameliorate hyperlipidemia, hyperglycermia and fatty liver |
Country Status (1)
Country | Link |
---|---|
TW (1) | TWI387460B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9895400B2 (en) | 2014-10-02 | 2018-02-20 | Genmont Biotech Inc. | Composition and use of Lactobacillus reuteri GMNL-263 in decreasing blood lipid levels |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102697060B (en) * | 2012-05-23 | 2014-04-09 | 广东省农业科学院农业生物技术研究所 | Bitter-gourd nutritious food with auxiliary hypoglycemic effect and preparation method thereof |
-
2009
- 2009-06-24 TW TW98121165A patent/TWI387460B/en active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9895400B2 (en) | 2014-10-02 | 2018-02-20 | Genmont Biotech Inc. | Composition and use of Lactobacillus reuteri GMNL-263 in decreasing blood lipid levels |
Also Published As
Publication number | Publication date |
---|---|
TW201100088A (en) | 2011-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6250157B2 (en) | Raw coffee bean extract and method thereof | |
JP4229942B2 (en) | Fat metabolism promoter or anti-diabetic agent | |
KR101756804B1 (en) | Functional composition for anti-inflammation and anti-diabetic comprising the extract from a leaf of Angelica gigas Nakai and manufacturing method for functional sauce using the same | |
CN1870986A (en) | insulin primordial stimulator | |
KR20160007728A (en) | Method for manufacturing garlic skin extract and food composition for preventing and alleviating diabetes prepared using the same | |
TWI387460B (en) | Extraction methods and compositions to ameliorate hyperlipidemia, hyperglycermia and fatty liver | |
KR100922606B1 (en) | Noodles and Manufacturing Method Using Jujube Powder and Jujube Seed Extract | |
JP5064652B2 (en) | Diabetes prevention and treatment composition and health food containing active ingredients thereof | |
WO1999025197A1 (en) | Fenugreek compositions having reduced taste and odor and methods of use | |
CN110624042B (en) | Composition for treating diabetic diseases | |
KR20130047458A (en) | Composition for preventing, improving, or treating a disease controlled by ppar action | |
WO2007100103A1 (en) | Ameliorating agent for metabolic syndrome | |
Ashraduzzaman et al. | Vigna unguiculata linn. Walp. Seed oil exhibiting antidiabetic effects in alloxan induced diabetic rats | |
KR20130083427A (en) | Composition for preventing, improving, or treating a disease controlled by ppar action | |
JP5872725B1 (en) | Dipeptidyl peptidase IV inhibitory composition derived from bonito | |
CN101057674A (en) | Composition for preventing and curing diabetes | |
JP2008099652A (en) | Health food for metabolic syndrome | |
KR101478196B1 (en) | Composition for the prevention of foods from oxidation and for retarding the onset of diabetes comprsing of the extract of Cudrania tricuspidata as a main component | |
JP5794678B2 (en) | Glucagon-like peptide-1 secretion promoter | |
WO2010116866A1 (en) | Agent for ameliorating or preventing metabolic syndrome | |
JP7505728B2 (en) | Oral Compositions | |
CN1678335A (en) | Agaricus Blazei Extract to Prevent Cancer Induction or Metastasis | |
KR102685818B1 (en) | A composition for improving and treating metabolic syndrome-related diseases caused by endocrine disruptors comprising benicasa hispida extract | |
JP2007151537A (en) | Useful material obtained from waste liquid of red bean, method for producing the same, and food and medicine containing the useful material | |
JP2008208081A (en) | Ampk activation agent |